Year Founded
2008
Ownership
Public
Employees
~100
Therapeutic Areas
GastroenterologyInfectious Diseases
Stage
Phase 2
Modalities
Other

Axcella Health General Information

Developing novel therapeutic candidates using endogenous metabolic modulators (EMMs) for complex diseases. Currently has programs in NASH, Long COVID, and muscle conditions.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
Cambridge, Massachusetts
United States

Drug Pipeline

AXA1125
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Axcella Health's pipeline data

Book a demo

Key Partnerships

CYTOO

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Axcella Health Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Axcella Health's complete valuation and funding history, request access »

Axcella Health Investors

Flagship Pioneering was the founding investor/founder.[5]
Investor Type: Venture Capital
Holding: Minority